SCHEMBL4797241

SCHEMBL4797241

C(#CC1CCCNC1)c1ccc2c(c1)[CH]N=CN2

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4797623 0.93 CSF1R (0.31) CSF1R
SCHEMBL5081045 0.87 ALDH2 (0.33)
SCHEMBL4799432 0.85 ALDH2 (0.35)
SCHEMBL193113 0.69 HTR2C (0.36) DRD2DRD3
Hydrochloric Acid SCHEMBL193729 0.68 HTR2C (0.36) DRD2DRD3
Hydrochloric Acid SCHEMBL30836067 0.65 HTR2C (0.42) CSF1R
Hydrochloric Acid SCHEMBL31556498 0.64 HTR2A (0.45) DRD2DRD3
SCHEMBL25785826 0.64 CSF1R (0.37) CSF1R
SCHEMBL25775970 0.64 CSF1R (0.37) CSF1R
SCHEMBL25775969 0.64 CSF1R (0.37) CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332493-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth OSI PHARMACEUTICALS (US) 2008-02-19 US disclosed
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 DRD2 4097/4885DRD3 3288/4885CSF1R 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.